Chronic hepatitis B
Conditions
Interventions
Case series:Stopped to observe
Sponsors
The Third People's Hospital of Shenzhen
Eligibility
Sex/Gender
Female
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: Pregnant women with HBeAg positive chronic hepatitis b, aged between 20 and 50 years old, HBV DNA=2×105 IU/ml (or 6 log10 copies/ ml) before taking the drug, started oral administration of tenofovir divir (TDF) between 24 and 28 weeks during pregnancy and stopped taking the drug immediately after delivery.
Exclusion criteria
Exclusion criteria: Co-infection with hiv-1, or hepatitis c, or syphilis; Renal insufficiency; Liver cancer or liver insufficiency; Creatinine clearance (CLCr) 5 times the normal upper limit; Total bilirubin > 2 mg/dL;Albumin < 25mg/L; Threatened abortion; Ultrasound indicated fetal malformation; Being treated with nephrotoxic drugs, steroids, cytotoxic drugs, non-steroidal anti-inflammatory drugs or immunomodulators; Receiving an organ or bone marrow transplant; Severe liver, kidney, cardiovascular, pulmonary, or neurological diseases or immunocompromised diseases (including malignancies) were determined by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| liver function;HBV DNA load;HBV serological markers; | — |
Countries
China
Contacts
Public ContactLiuqing Yang
The Third People's Hospital of Shenzhen
Outcome results
None listed